Acute cholestatic hepatitis after atorvastatin reintroduction;Hepatitis colestásica aguda tras la reintroducción de atorvastatina

Gastroenterologia y Hepatologia

Volumn 29, Issue 1, 2006, Pages 21-24

  De Castro, M L ^a,b   Hermo, J A ^a   Baz, A ^a   De Luaces, C ^a   Perez R ^a   Clofent, J ^a  

^a HOSPITAL DO MEIXOEIRO   (Spain)

^b 3   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PREDNISONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEPATITIS; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; CONVALESCENCE; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LABORATORY DIAGNOSIS; LIVER BIOPSY; MALE; TREATMENT WITHDRAWAL;

EID: 33644531031     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083248     Document Type: Article

References (20)

1. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of Atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998;158: 577-84.
2. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999;353:1763-4.
3. Jimenez-Alonso J, Osorio JM, Gutierrez-Cabello F, López de la Osa A, Leon L, Mediavilla JD. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med. 1999;159:1811-2.
4. Ridruejo E, Mandó OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol. 2002;37:165-6.
5. Gershovich OE, Lyman AE. Liver function test abnormalities and pruritus in a patient treated with Atorvastatin: Case report and review of the literature. Pharmacotherapy. 2004;24:150-4.
6. Sues M, Goldaracena M, Avila L, Crespo B. Consumo de hipolipemiantes en España, 1987-2000. Rev Esp Salud Pública. 2001;75:129-42.
7. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors. Drugs. 2001;61:197-206.
8. Bruguera M, Barrera JM, Corradi F, Mas A. Hipertransaminasemia superior a 400 U/l en adultos atendidos en un hospital terciario. Estudio prospectivo de su etiología. Gastroenterol Hepatol. 2005;28:15-9.
9. Bruguera M, Joya P, Rodés J. Hepatitis asociada al tratamiento con lovastatina. Presentación de 2 casos. Gastroenterol Hepatol. 1998;21:127-8.
10. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepaitis associated with pravastatin. Am J Gastroenterol. 1999;94: 1388-90.
11. Abourjaily HM, Alsheikh-Ali AA, Karas RH. Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Am J Cardiol. 2003;91:999-1002.
12. Barquero Romero J, Pérez Miranda M. Metformin-induced cholestatic hepatitis. Gastroenterol Hepatol. 2005;28:257.
13. Legaz Huidobro ML, Gonzalez Cairo P, Pérez Roldán F, Soto Fernández S, De Pedro Estebán A, Cuesta Domínguez R. Autoinmune hepatitis after risperidone-induced cholestatic hepatitis. Gastroenterol Hepatol. 2005;28:135-6.
14. Wierzbicki AS, Crook MA. Cholestatic liver dysfunction. Lancet. 1999;354:954.
15. Perger L, Kohler M, Fattinger K, Flury R, Mejer PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003; 39:1096-7.
16. Pelli N, Setti M. Atorvastatin as a trigger of autoinmune hepatitis. J Hepatol. 2004;40:716.
17. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci. 2000; 169:176-9.
18. Vermes A, Vermes I. Genetic polymorphism in cytochrome P450 enzymes: effect, efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovas Drugs. 2004;4:247-55.
19. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1289-92.
20. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol. 2004, 94 Suppl:30F-4F.